Fernando Doñate

Fernando Doñate has a diverse work experience spanning over several companies and roles. Fernando recently joined Adicet Bio, Inc in 2022 as the VP of Translational Medicine. Prior to that, they worked at Zentalis Pharmaceuticals as the VP of Biology from 2019 to 2022, where they focused on developing therapeutics for cancer patients. Before their time at Zentalis, they were the VP of Research at Targazyme in 2019. Fernando also served as a Biotech Consultant at Meditope, BCN Biosciences from 2018 to 2019. From 2010 to 2018, they held positions at Agensys/Astellas, starting as the Director of Translational Research and eventually becoming the Senior Director. Earlier in their career, they were the Executive Director Preclinical R&D at Proacta, Inc from 2008 to 2010, the Associate Director at Attenuon, LLC from 2000 to 2008, and a Senior Scientist at NuVas, LLC from 1997 to 2000. Fernando began their career as a Postdoctoral fellow at The Scripps Research Institute from 1995 to 1997.

Fernando Doñate holds a Bachelor's and Master's degree in Chemistry and Biology from Universidad Complutense de Madrid. Fernando also holds a Ph.D. in Chemistry and Biology from the University of Missouri-Kansas City. The specific start and end years for each of these degrees are not provided.